189 related articles for article (PubMed ID: 33894280)
1. Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study.
van Dalem J; Brouwers MCGJ; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Driessen JHM
Diabetes Res Clin Pract; 2021 Jun; 176():108828. PubMed ID: 33894280
[TBL] [Abstract][Full Text] [Related]
2. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
4. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
[TBL] [Abstract][Full Text] [Related]
5. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
[TBL] [Abstract][Full Text] [Related]
6. Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
Mahmoud F; Mueller T; Mullen A; Sainsbury C; Rushworth GF; Kurdi A
Diabetes Obes Metab; 2024 Jul; 26(7):2684-2694. PubMed ID: 38558305
[TBL] [Abstract][Full Text] [Related]
7. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
[TBL] [Abstract][Full Text] [Related]
8. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
[TBL] [Abstract][Full Text] [Related]
9. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines.
Wang TY; Eguale T; Tamblyn R
BMC Health Serv Res; 2013 Oct; 13():442. PubMed ID: 24160916
[TBL] [Abstract][Full Text] [Related]
10. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019.
Lee KA; Jin HY; Kim YJ; Im YJ; Kim EY; Park TS
J Korean Med Sci; 2021 Sep; 36(36):e230. PubMed ID: 34519186
[TBL] [Abstract][Full Text] [Related]
14. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
[TBL] [Abstract][Full Text] [Related]
15. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
16. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
Geier AS; Wellmann I; Wellmann J; Kajüter H; Heidinger O; Hempel G; Hense HW
Diabetes Res Clin Pract; 2014 Oct; 106(1):73-80. PubMed ID: 25139631
[TBL] [Abstract][Full Text] [Related]
17. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
Abrahami D; D'Andrea E; Yin H; Kim SC; Paik JM; Wexler D; Azoulay L; Patorno E
Diabetes Obes Metab; 2023 Oct; 25(10):2980-2988. PubMed ID: 37395339
[TBL] [Abstract][Full Text] [Related]
18. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
19. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
20. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
